Status:
RECRUITING
Exploring Brain Molecular Imaging and Blood Biomarkers in Subjects With Glucocerebrosidase Mutations: Toward a Precision Medicine Approach to Characterize Parkinson's Disease Clinical Trajectories
Lead Sponsor:
IRCCS San Raffaele
Collaborating Sponsors:
IRCCS National Neurological Institute "C. Mondino" Foundation
Conditions:
Parkinson Disease
Eligibility:
All Genders
18+ years
Brief Summary
Glucocerebrosidase (GBA) mutations are the most common risk factor for Parkinson's Disease (PD). GBA-related PD(GBA-PD) exhibits a more malignant phenotype as compared to no-carriers. Still, the mecha...
Eligibility Criteria
Inclusion
- PD diagnosis according to MDS-PD criteria and for GBA-PD group, presence of heterozygous GBA mutations;
- disease duration 3-7years.
Exclusion
- other neurological or systemic diseases;
- presence of mutations in another PD gene;
- impossibility or unwillingness to perform FDG-PET.
Key Trial Info
Start Date :
April 30 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 1 2026
Estimated Enrollment :
140 Patients enrolled
Trial Details
Trial ID
NCT06167603
Start Date
April 30 2023
End Date
April 1 2026
Last Update
February 1 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Neurological Institute Foundation Casimiro Mondino
Pavia, Italy